Member Info for rebarm

Felko, suggest you concentrate on the US if interested in MTFB's marketing efforts. Whilst listed on AIM, it is essentially a US company with a nasdaq listing, head office in NY and a BoD virtually all American (GL, a Brit, is domiciled in the US. The only one I'm not certain of is Chairman Richard Morgan also a Brit but who spends bulk of his time flitting between US and UK).

As you will know, number of commercial options under consideration but focus appears to be very much on the US market and a commercial partnership providing MTFB with ready made access to hospitals across the US. Faster and cheaper than doing it themselves. I'm sure that, despite your concerns, the management team don't spend all day in Wall Street bars sipping martinis! That's for next year after approval and commercialisation! Another way of me agreeing with The Italian's point!

Any concerns I might have are encapsulated by the mystifying sp activity or lack of it. Why has it not made better progress of late given the stage Iclaprim is now at? Perhaps Hanibal has a very valid point which could explain a lot.

Sheltie, all options have been mentioned at various times including the last AGM but no specific timescales. They appear to be separating the US from the rest of the world and concentrating currently on the US but considering options for both. If they go down the partnership route for the US then I would think an agreement would be in place prior to the FDA decision, Q1 2019, such that they can get the sales show on the road without any delay.

ST, no problem with your sentiments in general but your choice of words, 'like the other cowboy CEOs may be our CEO', your inference being that GL is a cowboy. I've met him on a number of occasions including 1to1 discussions and I can assure you he is no cowboy. My opinion is one I'm sure will be shared by other posters on this board many of whom know him a lot better than I do.

Anything said about commercialisation, including Ian B's link below, has been in broad general terms with little more detail other than possible options. I don't think you can expect more at this juncture as it could well result in MTFB's negotiating position being undermined. I'm sure you agree the closer that MTFB's negotiating cards are held to the corporate chest the better the potential outcome. Yes, more detail might boost the share price but surely only in the short term before we drift back to were we've been for an extended period.

Like every LTH, I would have liked to have seen a stronger sp performance particularly given the positive news - P3, NDA etc. However, FDA approval, if forthcoming, is less than 4 months away and, in the meantime, there may well be commercial announcement/s that have a positive effect. We're nearly over the line!!

You might like to re-phrase your post, GL is no cowboy!!

Thanks for posting. An excellent and very worthwhile read. Certainly increases confidence in FDA approval of Iclaprim.

Afternoon Ivy. Many thanks for posting the Zacks report. A compelling analysis well qualified and quantified. Certainly helps to allay any concerns I may have about future commercial prospects particularly as the target $28 per share is based only on treatment for ABSSSI.

Ivy/Jackdaw, thanks for your responses last night and this morning both of which were helpful.

Any new drug treatment being progressed through development, trials and approval is like playing with a monster jigsaw - difficult to piece together. Situation exacerbated when developer is an AIM sized biotech and further still when, as PIs, we don't have all the pieces!! We've got most of the pieces now, or so we think, and puzzle nearly complete. Very much a case of patience for a further 6 months although despite reassurances I'm still concerned about market penetration following approval and commercial deal.

Some excellent contributions over the weekend. Many thanks all. Hope you managed some time off for a beer/glass of wine unless you were drinking on the job!! Some comments
Firstly, Ivy, thanks for the link to the Dr O’Riordan video. A positive endorsement. I’ve done some digging and he, along with many other highly regarded medics in the microbiology space, have co-authored papers on the Iclaprim trial results with David Huang. Most of these individuals are US based but two in the UK. They all appear to be associated with highly regarded institutions, such as Duke University, and going by their CVs in influential positions. For example, the UK contributors include Prof Mark Wilcox who advises the NHS on antimicrobial resistance. Their endorsement of Iclaprim will undoubtedly be extremely important come approval and commercialisation.

Totally agree Ivy with your list of reasons why FDA approval is now a distinct possibility. However, one concern that I have had which unfortunately has been reinforced by Laggan and Stebol and then Staggart yesterday and that is the scale of the commercial opportunity. The potential US market, as referenced in MTFB presentations, is substantial but the actual addressable market will be much smaller, but I can’t quantify. What is fueling my concern is the increasing cost pressures the provision of healthcare, public and private, is under in the West. Drug costs are an important consideration and an easy one to reduce particularly with the pressure being applied through the media on the pharma sector. How does that affect the commercial opportunity for Iclaprim?

The current SoC for the treatment of gram-positive infections is Vancomycin. Whilst Iclaprim has been proven to be safer and more efficacious, Vancomycin is well established and, thanks to multiple generics, cheap. Iclaprim cannot and should not compete on a price basis. I may need correcting on this, but I believe that in large medical institutions there will be a purchasing department responsible for sourcing drugs and measured on short term budget considerations and cost savings and, despite possible pressure from medical colleagues, will look primarily at the price tag……….1st choice Vancomycin. To be successful commercially, MTFB and partner/s must be going to market with a detailed cost/benefit analysis that factors in the many other benefits of Iclaprim that we are aware of. Full circle back to my opening para, the nurturing and endorsements of these heavy weight and influential doctors will have a significant bearing on the success of Iclaprim and I will be watching for any further articles and/or public pronouncements coming from them supporting Iclaprim.

Apologies for the length of this but concerned not about the short-term approval cycle but the longer-term commercial implications. Appreciate any feedback that will allay these concerns. I’m sure I’m not the only one!!

Wildbunch, they were in touch with 'interested parties' before they announced P3 failure and that was back in April!! One would have thought there might have been some progress worthy of reporting since then! Or does the extended silence suggest not a lot of interest?

Odeffer, thanks for posting the mail from IMM's investor relations department. They state,'We will update the market when there is confirmed progress to report' Presumably they've all been on a beach somewhere since April? Given the shambolic trial and inevitable result, surely a simple update on what they are doing/planning would be common sense. That at least would be some progress!

The only news that will move the sp up is an RNS announcing the sacking of Tim McCarthy closely followed by one announcing the resignation of Robert Zimmer!

Morning Ivy. Given the attendee profile, the subject matter of David Huang's presentation and that of the posters I wonder whether this conference is being used by MTFB as a warm-up act for an EMA approval submission. Recall from the recent AGM that it wasn't top priority and that the process is somewhat different to that for the FDA, a lot of what has been done in preparing the NDA must be reusable. Further, if that process is being kicked off and is meeting no resistance from the EU then it has to be another plus for MTFB's commercial negotiations

You're spot on about the mystery

Ivy, was it a single trade? Reason for asking is that on HL the total day's volume is down as 4.749m and the biggest individual trade by volume is 4m followed by one at 332,000. Checking on LSE they show a sell of 3m at 15:49 which was cancelled immediately. If for whatever reason that wasn't cancelled out on Peel's Twitter group numbers just about balance. As you say it's a mystery.

Rocktapper, agreed. Good interview, such a pity the RNS wasn't as clear as we might have avoided today's drop. Hopefully a gross overreaction and sp will start a recovery tomorrow before the weekend.

Belgrano, thanks for posting the response from Dr Cath O'Neill to your query. I reckon this afternoon's interview was prompted by market reaction to the RNS and I'm pleased that most of the concerns expressed on this board today were responded to.

Belgrano, thanks for the advice but I'm already fully invested here, thankfully at an average somewhat lower than today's close. Gives me room to spare in event of anymore stupid RNSs!! Good luck anyway.

Soulsister, if that question was directed at me, not referring to a specific article but at today's first RNS.

Belgrano, you're spot on with that. Badly worded bordering on the naive. Whilst I rate our CEO for the work she's done and her open manner, I do think that there are too many CEOs/founders of AIM biotech/life science start-ups with scientific and/or academic backgrounds who have discovered something of potential value, clinically and commercially, and think the fund raising, trialing, commercialisation is a straightforward set of tasks requiring no new skills. Any combination of reasons - naivety, ill-informed, innocence or arrogance - resulting in failure to recognise the sensitivity of the market and how it can react. Today is a case in point and, I hope, a salutary lesson for SBTX's CEO.

V, I see you're getting some stick over on ADVFN! Shame that there appears no room for constructive debate particularly around something that imo should be a concern. One comment along the lines of, ' they just have to prove that the cream lasts for an extended period' should be red flag, hopefully only temporary, given trials are supposed to start next month!!

Got it now on LSE

A sell of 11m+ at 32:50p timed 16:03 is visible on the HL website under MTFB recent trades. I can't see anywhere else where I have access. Is this genuine? If so any ideas on who the seller might be? Doesn't seem to have had any effect on the sp